Assessment of cytoplasmic positivity for VEGF was significantly reduced in tumors treated with the triple-drug combination (6.36%) (specified by red arrows in Figure 2when compared with tumor-control (TC) group, which exhibited the highest (70.61%) level of cytoplasmic positivity (black arrows indicated in Figure 2A-i). The gene discussed is VEGFA; the disease is neoplasm.